PXT002331 A Phase I, Double Blind, Placebo Controlled, First in Human, Single and Multiple Ascending Oral Dose, Safety, Tolerability and Pharmacokinetic Study in Healthy Male and Female Subjects

Trial Profile

PXT002331 A Phase I, Double Blind, Placebo Controlled, First in Human, Single and Multiple Ascending Oral Dose, Safety, Tolerability and Pharmacokinetic Study in Healthy Male and Female Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 04 Oct 2016

At a glance

  • Drugs Foliglurax (Primary)
  • Indications Parkinson's disease
  • Focus Adverse reactions; First in man
  • Sponsors Prexton Therapeutics
  • Most Recent Events

    • 27 Sep 2016 Status changed from recruiting to completed.
    • 28 Jan 2016 Status changed from not yet recruiting to recruiting, as reported by ClinicalTrials.gov.
    • 30 Dec 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top